Skip to main content
TipRanks
Go Ultimate75% OFF

Towa Pharmaceutical Co (TWAPF) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Towa Pharmaceutical Co has a market cap or net worth of $1.03B. The enterprise value is $352.30B.

Market Cap
$1.03B
Enterprise Value
$352.30B

Share Statistics

Towa Pharmaceutical Co has 51,516,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
51,516,000
Owned by Insiders
―
Owned by Institutions
10.14%

Financial Efficiency

Towa Pharmaceutical Co’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 2.25%.

Return on Equity (ROE)
0.03
Return on Assets (ROA)
0.01
Return on Invested Capital (ROIC)
2.25%
Return on Capital Employed (ROCE)
0.06
Revenue Per Employee
55.60M
Profits Per Employee
1.07M
Employee Count
4,923
Asset Turnover
0.58
Inventory Turnover
1.41

Valuation Ratios

The current PE Ratio of Towa Pharmaceutical Co is 43.59. Towa Pharmaceutical Co’s PEG ratio is -0.54.

PE Ratio
43.59
PS Ratio
0.60
PB Ratio
0.89
Price to FCF
39.70
Price to Operating Cash Flow
6.73
PEG Ratio
-0.54

Income Statement

In the last 12 months, Towa Pharmaceutical Co had revenue of 273.71B and earned 5.25B in profits. Earnings per share was 106.65.

Revenue
273.71B
Gross Profit
99.10B
Operating Income
23.10B
Pretax Income
13.16B
Net Income
5.25B
EBITDA
38.26B
Earnings Per Share (EPS)
106.65

Cash Flow

In the last 12 months, operating cash flow was 26.71B and capital expenditures -15.84B, giving a free cash flow of 10.87B billion.

Operating Cash Flow
26.71B
Free Cash Flow
10.87B
Free Cash Flow per Share
87.02

Dividends & Yields

Towa Pharmaceutical Co pays an annual dividend of $0.25, resulting in a dividend yield of 1.95%

Dividend Per Share
$0.25
Dividend Yield
1.95%
Payout Ratio
19.88%
Free Cash Flow Yield
2.60%
Earnings Yield
2.37%

Stock Price Statistics

Beta
0.49
52-Week Price Change
2.57%
50-Day Moving Average
25.90
200-Day Moving Average
25.08
Relative Strength Index (RSI)
94.95
Average Volume (3m)
―

Important Dates

Towa Pharmaceutical Co upcoming earnings date is Feb 15, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 11, 2026
Next Earnings Date
Feb 15, 2027
Ex-Dividend Date
Mar 31, 2026

Financial Position

Towa Pharmaceutical Co as a current ratio of 2.76, with Debt / Equity ratio of 127.31%

Current Ratio
2.76
Quick Ratio
1.49
Debt to Market Cap
1.08
Net Debt to EBITDA
4.74
Interest Coverage Ratio
10.22

Taxes

In the past 12 months, Towa Pharmaceutical Co has paid 7.91B in taxes.

Income Tax
7.91B
Effective Tax Rate
0.60

Enterprise Valuation

Towa Pharmaceutical Co EV to EBITDA ratio is 11.72, with an EV/FCF ratio of 78.04.

EV to Sales
1.17
EV to EBITDA
11.72
EV to Free Cash Flow
78.04
EV to Operating Cash Flow
13.23

Balance Sheet

Towa Pharmaceutical Co has $60.07B in cash and marketable securities with $229.74B in debt, giving a net cash position of -$169.67B billion.

Cash & Marketable Securities
$60.07B
Total Debt
$229.74B
Net Cash
-$169.67B
Net Cash Per Share
-$3,293.48
Tangible Book Value Per Share
$3,403.45

Margins

Gross margin is 36.20%, with operating margin of 8.90%, and net profit margin of 1.37%.

Gross Margin
36.20%
Operating Margin
8.90%
Pretax Margin
3.90%
Net Profit Margin
1.37%
EBITDA Margin
9.99%
EBIT Margin
4.04%

Analyst Forecast

The average price target for Towa Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
1.51%
EPS Growth Forecast
-81.66%